The Cigna Group (CI) fair value analysis
S&P 500 · Updated 2026-10-19
CI price how computed
Forward Fair Value verdict
UndervaluedCI is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $282.43
- Sector
- Healthcare
- 12-month range
- $244.41–$309.18
- Market cap
- $74.6B
- From 52-week high
- -8.7%
- Shares outstanding
- 264M
- Rank in Healthcare by discount to fair value
- #28 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
The Cigna Group is a healthcare company that provides health insurance, medical services, and pharmacy benefits to individuals and employers. The company operates globally with a significant presence in the United States and maintains operations in numerous international markets.
CI currently ranks #28 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $74.6B
- P/E (trailing)
- 9x
- Revenue (TTM)
- $282B
- Net margin
- 2.3%
- EPS (TTM)
- $31.48
- Gross margin
- 20.9%
- Debt / equity
- 0.75
- Revenue growth (3-yr avg)
- 15.4%
- Shares outstanding
- 264M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 75 · overbought
- 50-day average
- $278.92
- 200-day average
- $280.43
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $6.19 per share (4 payments)
- Yield on last price
- 2.19%
- Consecutive years of increases
- 5
- Last ex-dividend date
- 2026-09-08
- Last payment date
- 2026-09-23
Earnings how computed
- Next earnings report
- 2026-11-05 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+2.6%)
2026-03 ▲ beat (+2.4%)
2025-12 ▲ beat (+2.5%)
2025-09 ▲ beat (+2.5%)
2025-06 ▲ beat (+0.7%)
2025-03 ▲ beat (+6.1%)
2024-12 ▼ miss (-15.1%)
2024-09 ▲ beat (+3.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 18 buy · 6 hold · 0 sell (24 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $342
- Target vs last price
- +21.1%
What our data shows for CI
- Our model validated 17 trailing price-to-earnings windows for CI, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $244.41–$309.18.
- The 14-day relative strength index sits at an overbought 75.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CI
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CI news
TickrTrends' derived news-sentiment signal for CI is currently leaning positive, computed from recent coverage.
- Cigna: Deeply Undervalued With Double-Digit EPS Growth Ahead (NYSE:CI) (seekingalpha.com, 2026-10-01)
TickrTrends take: Cigna trades at a valuation that TickrTrends currently classifies as undervalued within the Healthcare sector, positioning the stock for potential appreciation if earnings growth materializes as anticipated. An investor focused on valuation metrics should monitor whether the company delivers on the double-digit earnings per share growth outlined in the headline, as actual execution would reinforce the undervalued assessment. The combination of current price levels and projected earnings expansion creates a scenario where valuation multiples could compress or the stock price could rise to reflect normalized market pricing. - The Cigna Group (CI) Analyst/Investor Day - Slideshow (NYSE:CI) 2026-09-30 (seekingalpha.com, 2026-09-30)
TickrTrends take: CI held an Analyst/Investor Day on September 30, 2026, where the company presented strategic updates and forward guidance to the investment community. According to TickrTrends' current valuation analysis, CI is assessed as undervalued within the Healthcare sector, suggesting that market pricing may not fully reflect the company's intrinsic value or growth prospects. A valuation-focused reader should monitor whether the company's presentations at such events contain information about earnings trajectories, margin expansion, or capital allocation plans that could validate or challenge the undervalued assessment. - Cigna (CI) Unveils $3 Billion AI Initiative, Reaffirms 2026 Guidance Amid Strong Dividend Profile (gurufocus.com, 2026-09-30)
TickrTrends take: Cigna's announcement of a substantial AI initiative signals management confidence in the company's long-term operational efficiency and earnings potential, which aligns with TickrTrends' undervalued assessment. The reaffirmation of 2026 guidance provides visibility into earnings trajectory, a key metric for valuation models, while the company's strong dividend profile offers current yield support for shareholders. For valuation-focused investors, monitoring whether the AI investment translates into margin expansion or revenue acceleration in coming quarters will be critical to validating whether the current undervalued positioning reflects genuine upside potential.
What people are saying
Follow the CI conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for CI in the Healthcare sector showed a shift this week as the Relative Strength Index moved from a neutral zone into overbought territory. The current valuation verdict for the stock remains Undervalued despite this technical indicator change.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for CI in the Healthcare sector show movement this week, with the sector discount rank improving from number 39 to number 33. The current valuation verdict remains Undervalued.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CI stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), CI is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is CI's TickrTrends verdict?
CI's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does CI compare to other Healthcare stocks?
CI ranks #28 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is CI overbought or oversold?
CI's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does CI pay a dividend?
Yes. CI paid $6.19 per share over the last twelve months (4 payments), a 2.19% yield on TickrTrends' last price, and has raised the annual total for 5 consecutive years. The last ex-dividend date was 2026-09-08.
When does CI report earnings next?
CI's next earnings report is scheduled for 2026-11-05 (pre-market), per the published earnings calendar.
Does CI usually beat earnings estimates?
Over its last 8 reported quarters CI beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CI?
Of 24 analysts covering CI, 18 rate it a buy, 6 a hold and 0 a sell - buy-leaning, with a consensus price target of $342 (+21.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
CI vs ABT · CI vs AMPH · CI vs DVA · CI vs HALO · CI vs HSTM